Stocks and Investing
Stocks and Investing
Tue, May 10, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, May 9, 2022
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BGNE) at Buy with Decreased Target to $300 on, May 9th, 2022
Matthew Harrison of Morgan Stanley, Maintained "BeiGene, Ltd." (BGNE) at Buy with Decreased Target from $338 to $300 on, May 9th, 2022.
Matthew has made no other calls on BGNE in the last 4 months.
There is 1 other peer that has a rating on BGNE. Out of the 1 peers that are also analyzing BGNE, all agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $177 on, Thursday, March 17th, 2022
Contributing Sources